Loading…
Grand Pharma's subsidiary agreed to acquire Nanjing Kainite Medical Technology through a series of capital subscriptions and share purchases totaling CNY 29.4 million, with an additional CNY 100 million capital injection into a fund, to build a pan-interventional diagnosis and treatment platform.
“待完成股本认购事项及收购事项后,远大医药将会持有目标公司的100%股本权益。”beta.zhitongcaijing.com
Summarized from public sources; check the original articles before acting on it.